In this Review, Brouns and colleagues discuss our current understanding of RNA-targeting type III and type VI CRISPR–Cas systems by detailing their composition, properties and defence processes, and describing the biological rationale behind the broad activated immune responses as an effective strategy to combat viral infection.
- Sam P. B. van Beljouw
- Jasper Sanders
- Stan J. J. Brouns